FGL

FGL, also written FGLL or the FG-loop peptide, is a synthetic 15-amino-acid peptide corresponding to the FG loop of the second fibronectin type-III module of the neural cell adhesion molecule (NCAM). It was designed in Danish academic neuroscience laboratories as a mimetic that reproduces the precise surface NCAM uses to bind and activate fibroblast growth factor receptor 1 (FGFR1) ^[4].

Because NCAM signaling through FGFR1 governs neuronal development, survival, and synaptic plasticity, FGL was created to engage that pathway pharmacologically. Across a decade of rodent work it has been studied as a cognitive enhancer and neuroprotective agent, penetrating into blood and cerebrospinal fluid after both subcutaneous and intranasal administration ^[4].

Its research applications are broad within preclinical neuroscience. FGL facilitates long-term potentiation and long-lasting synaptic plasticity in the hippocampus and dentate gyrus of living animals ^[1][3]; it accelerates early postnatal sensorimotor development and prolongs social-memory retention ^[4]; and it protects hippocampal CA1 neurons and rescues memory in models of amyloid-beta toxicity relevant to Alzheimer's disease ^[2]. Much of this work grew from interest in NCAM's role in stress, aging, and neurodegeneration.

FGL is not an approved drug and has no established human indication, but the common claim that it never reached people is wrong. Its dimeric form, written FGL(L), went through a phase 1 study: 24 healthy men, single intranasal doses of 25, 100 and 200 mg, all three well tolerated, no notable abnormalities in ECG recordings, vital signs or laboratory tests, and five adverse events in three subjects (13 percent), chiefly a burning sensation in the nose lasting under three minutes ^[6]. That is the whole human record. No phase 2 result has ever been published and no FGL trial is registered on ClinicalTrials.gov, so repeated dosing, clinical benefit and safety beyond a single day are all unstudied in people. Its human safety and long-term effects are not yet characterized, and three rodent studies noted that FGL given to healthy, uninjured tissue reduced CA1 pyramidal-cell counts ^[2][13][22], underscoring that its effects are context-dependent ^[2].

The human safety record is one single-dose study. FGL(L) given intranasally at 25, 100 and 200 mg was well tolerated in 24 healthy men, with no notable abnormalities in ECG recordings, vital signs or laboratory tests; three subjects reported five adverse events between them, mostly a burning sensation in the nose lasting under three minutes at the 200 mg dose, and runny eyes in one subject at 25 mg ^[6]. The same paper reports that rats, dogs and monkeys showed exposure in plasma and cerebrospinal fluid with no systemic toxicity after parenteral or intranasal dosing ^[6]. Nothing has been published on repeated dosing in humans, on injected FGL in humans, or on any human exposure beyond a single day.

Two groups of animal findings deserve to be read before the mechanism story. First, seizure threshold: in the mouse amygdala kindling model, 2 and 10 mg/kg FGL both significantly reduced the number of stimulations needed to trigger a generalised seizure, and the authors wrote that the result raises concern about promoting a hyperexcitable network ^[23]. Second, healthy tissue: three separate studies found FGL reducing a cell population in animals that were not injured. Young adult rats given FGL with no amyloid insult lost about 40 percent of their dorsal CA1 pyramidal cells ^[2]; healthy 4-month-old rats showed reduced dorsal hippocampal volume with fewer CA1 and CA3 pyramidal neurons ^[22]; and in aging rats FGL prevented stress-induced memory loss while reducing survival of newly generated hippocampal cells ^[13]. The protection in injury models is real and reproducible, and the same peptide is not neutral in an uninjured brain.

One behavioural effect belongs here rather than in the benefits: in rats, FGL(L) was acutely anxiogenic, with the antidepressant effect appearing only after chronic dosing ^[29].

Source purity is worth verifying, as with anything sold as a research peptide.

The programme reached people. In an 8-day open-label phase 1 study, 24 healthy male volunteers received single ascending intranasal doses of FGL(L) at 25, 100 and 200 mg; all three were well tolerated, and the report closed by saying further studies were being planned in patients with Alzheimer's disease ^[6]. Those studies were never published. Papers as late as 2014 still described the peptide as being in clinical development for neurodegenerative disease and brain insults ^[23], and ENKAM authors appear on work through 2016 ^[25], but no phase 2 result exists in the literature and no FGL trial is registered on ClinicalTrials.gov. What that means in practice is that FGL cleared the lowest bar a drug candidate has to clear and then stopped, for reasons that were never published.

FGL is well regarded in the NCAM literature for a specific reason: it engages a native growth-factor circuit rather than pushing a neurotransmitter, and the pathway it engages was mapped structurally before the peptide was built. It came out of the Protein Laboratory at the University of Copenhagen and has been characterised across roughly thirty rodent papers, in which it sharpened spatial learning, strengthened synaptic transmission, protected neurons against amyloid-beta and ischemia, and facilitated long-term potentiation for up to 24 hours from one dose ^[3].

The reputation is narrower than the paper count suggests. Most of the cognitive and neuroprotective work traces to that one group and the company it spun out, ENKAM Pharmaceuticals. Independent laboratories have replicated the in vitro ischemia protection ^[27] and produced the stem cell and stroke results ^{[24] [25]}, and an independent group also produced the seizure-threshold finding that nobody in the original programme reported ^[23]. In healthy uninjured tissue the peptide reduces neuron counts ^{[2] [22]}, so its actions are genuinely context-dependent rather than uniformly protective. Among people who sell peptides it is a deep cut; among people who study NCAM it is a well-known tool compound whose clinical programme stopped after phase 1.